Xencor's Coming Share Issue To Help Fund Immuno-Oncology Pipeline
Monrovia, California-based Xencor Inc.'s latest funding exercise is a public share offering to raise some $110m after expenses to advance its immuno-oncology pipeline.
You may also be interested in...
Scrip spoke with executives from five companies about challenges that remain for the burgeoning – but still young – immuno-oncology field in Part 2 of a wide-ranging roundtable discussion.
Scrip spoke with five companies about their places in the crowded IO field in which big pharma and small biotech firms alike are seeking the best options for harnessing the immune system to fight cancer.
Glenmark’s president and chief scientific officer, Dr Kurt Stoeckli, believes that some big pharma companies may have missed the opportunity to embark on immunotherapy cancer treatment R&D “at the right time” and tells Scrip that there is room for the Indian firm to provide competitive assets in the space. Stoeckli, an ex-Sanofi senior executive, also outlines why the upside potential of Glenmark’s BEAT antibody technology platform is “remarkable”.